OncoMatch/Clinical Trials/NCT07416123
A Study of GEN1106 in Participants With Solid Tumors
Is NCT07416123 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies GEN1106 for solid tumors.
Treatment: GEN1106 — The purpose of this trial is to learn about the safety and effectiveness of GEN1106 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1106 to find out if it is safe and determine what are the best doses to use. The second and third parts continues to test the safety of and how well GEN1106 works in additional participants with a specific cancer type and at doses chosen based on results from the first part of the trial. For each participant, the trial will last approximately 17 months but will vary for each person. This includes up to 21 days for screening prior to receiving trial treatment, approximately 5 months of treatment (the duration of treatment may vary for each participant), and approximately 11 months of follow up after trial treatment ends (the duration of follow up may vary for each participant). Participation in the trial will require visits to the site, with more frequent visits during the first 6 weeks of treatment and then less frequent visits afterwards. At site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, computed tomography \[CT\] scans) to monitor whether the treatment is safe and effective. All participants will receive active drug; no one will be given placebo.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Urothelial Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
Have progressed on or after standard of care (SoC) therapy, which should include chemotherapy
Must have received: anti-PD-1 therapy
Have progressed on or after standard of care (SoC) therapy, which should include ... anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapies
Must have received: anti-PD-L1 therapy
Have progressed on or after standard of care (SoC) therapy, which should include ... anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapies
Must have received: antibody-drug conjugate (enfortumab vedotin)
Have progressed on or after standard of care (SoC) therapy, which should include ... enfortumab vedotin (EV), if applicable for the tumor type
Cannot have received: topoisomerase 1 inhibitor-based antibody-drug conjugate
Prior treatment with topoisomerase 1 inhibitor-based antibody-drug conjugate (ADC) therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- START New York Long Island LLC · Lake Success, New York
- Carolina Urologic Research Center · Myrtle Beach, South Carolina
- South Texas Accelerated Research Therapeutics · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify